Clinical Takeaway
Cannabis use for anxiety showed different daily and long-term effects depending on whether people used flower or edible products, and the THC-to-CBD ratio mattered. Both product types reduced anxiety symptoms over time, but the speed and degree of relief varied by formulation and delivery method. Patients considering cannabis for anxiety should discuss specific product types with their clinician, as not all cannabis is equivalent in its anxiolytic effects.
#8 Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.
Citation: Rosa Luiza et al.. Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.. International journal of environmental research and public health. 2026. PMID: 41752306.
Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2
This study provides critical longitudinal data on differential anxiolytic efficacy between cannabis product types, addressing a significant gap in clinical evidence where patient-reported anxiety relief often contradicts pharmacological theory regarding THC’s anxiogenic properties. The finding that flower and edible products produce varying daily and sustained effects on anxiety has direct implications for product-specific clinical recommendations and dosing strategies in emerging cannabis-based anxiety treatment protocols. Understanding these product-dependent therapeutic outcomes is essential for clinicians advising patients on cannabis use and for informing evidence-based cannabinoid therapy development.
Quality Gate Alerts:
- Preclinical only
Abstract: Research shows that delta-9-tetrahydrocannabinol (THC) is linked to increased anxiety, while cannabidiol (CBD) may have anxiolytic effects. Cannabis use is often driven by coping with anxiety, though its daily impact on anxiety remains unclear. This study examined daily associations between cannabis use and anxiety across 30 days in adults who wanted to use cannabis for anxiety relief. Participants (N = 345) used flower or edible products ad libitum and were randomly assigned to groups by product type (CBD, THC, or THC + CBD). Each day, participants reported cannabis use in the past 24 h and rated their anxiety. Linear mixed-effects models tested whether anxiety changed over time, differed by cannabinoid group, and varied with use. Anxiety significantly decreased over the study period in both flower and edibles groups. In the flower group, THC + CBD and CBD products had greater decreases in anxiety (39.5% and 34.8%, respectively) compared to THC products (7.8%). In the edibles group, when participants used CBD products, this was associated with a 24.9% reduction in anxiety over the 30 days. Findings underscore the importance of distinguishing cannabis effects by product type and cannabinoid composition and suggest that CBD-dominant edibles were associated with less anxiety over time in this naturalistic study.
🧠 This longitudinal study offers a useful naturalistic glimpse into how different cannabis product types may differentially affect anxiety over time, though several limitations warrant cautious interpretation. The distinction between flower and edible formulations is clinically relevant since they differ in cannabinoid ratios, onset kinetics, and dosing precision, yet the study design lacks standardized cannabinoid quantification and relies on self-reported anxiety measures without controlling for baseline severity, concurrent medications, or other coping strategies that may confound daily improvements. The ad libitum dosing approach reflects real-world use patterns but undermines causal inference, as patients may naturally titrate toward products they find effective or away from those that worsen symptoms, creating selection bias within the study population. While the finding that product type matters for anxiety outcomes is promising and aligns with our mechanistic understanding of THC and CBD, clinicians should counsel patients that individual variability is substantial and that daily cannabis use carries its own risks including dependence potential and possible cognitive effects. Until we have rigorous
| |